C4 Therapeutics Inc (CCCC)vsRevolution Medicines Inc (RVMD)
CCCC
C4 Therapeutics Inc
$3.85
-7.67%
HEALTHCARE · Cap: $393.62M
RVMD
Revolution Medicines Inc
$155.69
+4.02%
HEALTHCARE · Cap: $32.71B
Smart Verdict
WallStSmart Research — data-driven comparison
C4 Therapeutics Inc generates 4745% more annual revenue ($35.95M vs $742,000). RVMD leads profitability with a 0.0% profit margin vs -292.1%. CCCC earns a higher WallStSmart Score of 34/100 (F).
CCCC
Avoid34
out of 100
Grade: F
RVMD
Avoid24
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+63.3%
Fair Value
$4.99
Current Price
$3.85
$1.14 discount
Intrinsic value data unavailable for RVMD.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Revenue surging 112.8% year-over-year
Conservative balance sheet, low leverage
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -44.3% — below average capital efficiency
0.0% earnings growth
0.0% margin — thin
Operating margin of 0.0%
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : CCCC
The strongest argument for CCCC centers on Price/Book, Revenue Growth, Debt/Equity. Revenue growth of 112.8% demonstrates continued momentum.
Bull Case : RVMD
The strongest argument for RVMD centers on Debt/Equity.
Bear Case : CCCC
The primary concerns for CCCC are EPS Growth, Market Cap, Piotroski F-Score.
Bear Case : RVMD
The primary concerns for RVMD are EPS Growth, Profit Margin, Operating Margin.
Key Dynamics to Monitor
CCCC profiles as a hypergrowth stock while RVMD is a value play — different risk/reward profiles.
CCCC carries more volatility with a beta of 2.78 — expect wider price swings.
CCCC is growing revenue faster at 112.8% — sustainability is the question.
CCCC generates stronger free cash flow (-30M), providing more financial flexibility.
Bottom Line
CCCC scores higher overall (34/100 vs 24/100) and 112.8% revenue growth. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
C4 Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
C4 Therapeutics, Inc., a biopharmaceutical company, develops new therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. The company is headquartered in Watertown, Massachusetts.
Revolution Medicines Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?